Ventyx Biosciences, Inc. (VTYX)
After hours:
| Previous close | 3.7400 |
| Open | 3.7800 |
| Bid | 4.6700 x 200 |
| Ask | 4.7000 x 300 |
| Day's range | 3.7450 - 4.9125 |
| 52-week range | 1.8650 - 40.5800 |
| Volume | |
| Avg. volume | 4,048,788 |
| Market cap | 329.936M |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.3000 |
| Earnings date | 25 Mar 2024 - 29 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.80 |
ZacksWhat Makes Ventyx Biosciences (VTYX) a New Buy Stock
Ventyx Biosciences (VTYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GlobeNewswireVentyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson’s disease and obesity in H2 2024 Topline Phase 2 data for VTX2735 in CAPS patients establish clinical proof of concept; Ventyx is planning to evaluate VTX2735 in cardiovascular diseases Early Phase 2 open-label extension data continue to support the clinical profile of VTX002 in ulcerative colitis; Ventyx is planning to seek a pa
- GlobeNewswire
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share in a private placement to certain qualified institutional buyers and ins
